The University of Oxford has launched Phase 1 trials for its Bundibugyo Ebola vaccine candidate. The Serum Institute of India has manufactured 620,000 doses to support the initiative. This development matters for vaccine preparedness against emerging viral threats.
The University of Oxford has begun human testing for a new vaccine candidate, ChAdOx1 BDBV, designed to target the Bundibugyo Ebola virus. This Phase 1 trial involves 50 healthy volunteers aged 18 to 55 and is the first time a vaccine for this specific strain of the virus has entered human clinical evaluation.
The vaccine uses viral vector technology, which is the same platform behind the Oxford/AstraZeneca COVID-19 vaccine. By building on this established technology, researchers aim to accelerate the development timeline. The Serum Institute of India (SII) has played a key role in the production process by manufacturing approximately 620,000 doses. While 4,000 doses are currently designated for the clinical trial, the remaining stockpile is maintained to allow for a rapid response if the vaccine passes its safety and effectiveness tests.
The Bundibugyo Ebola virus is considered a major health concern, as it is responsible for the third-largest Ebola outbreak ever recorded. The financial support for this project comes from the Coalition for Epidemic Preparedness Innovations (CEPI), which has provided $8.6 million to move the candidate from research to the testing stage.
For the Serum Institute of India, this project demonstrates its ongoing role in global vaccine manufacturing partnerships, particularly for large-scale production of experimental vaccines. Investors and observers often look at such partnerships as a indicator of a company’s operational capacity to handle complex, large-scale medical manufacturing, although the commercial viability of such vaccines typically depends on international health agency contracts and emergency procurement needs. The next phase for the project will be to review data from these initial 50 participants to determine safety and the immune response generated by the vaccine.